Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
Piccin
Andrea
A
Cortelazzo
Sergio
S
Rovigatti
Ugo
U
Bourke
Billy
B
Smith
Owen P
OP
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002897:Chromosomes, Human, Pair 7; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000601:surgery; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019804:Mesalamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008780:Methyltransferases / Q000172:deficiency / Q000235:genetics; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000235:genetics / Q000276:immunology / Q000601:surgery; D011241:Prednisone / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
D007166:Immunosuppressive Agents; D003561:Cytarabine; D019804:Mesalamine; D019819:Budesonide; D005047:Etoposide; D015122:Mercaptopurine; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D011241:Prednisone; D015255:Idarubicin